Cytopathology

AIxMed Welcomes Barbara Crothers, D.O., as Chief Scientist and Appoints Two Scientific Advisors

Retrieved on: 
Monday, June 5, 2023
ASC, University, College, JPC, Urine, D.O, Consultant, CAP, Cancer, Bladder cancer, Digital Pathology Association, Medicine, University of Pittsburgh School of Medicine, Associate, TPS, DPA, American Society of Cytopathology, Pathology, Artificial intelligence, Department of Defense Veterinary Pathology Residency, Digital, Federation, Health, Wilfrid Sellars, Society, Cell biology, Johns Hopkins School of Medicine, Medical device, Medical imaging, Nursing, AIXM, United States Army, Cytopathology

SANTA CLARA, Calif., June 5, 2023 /PRNewswire/ -- AIxMed, an early-stage smart Cytology company at the intersection of artificial intelligence (AI) and medicine, announced the appointment of Cytopathology industry heavyweight Barbara Crothers, D.O., as Chief Scientist. In this new executive leadership role, Dr. Crothers will drive AIxMed's strategic scientific and clinical initiatives. This includes leading U.S.-based pilot and validation studies of the AIxMed digital Cytology platform.

Key Points: 
  • In this new executive leadership role, Dr. Crothers will drive AIxMed's strategic scientific and clinical initiatives.
  • This includes leading U.S.-based pilot and validation studies of the AIxMed digital Cytology platform.
  • Dr. Crothers is joining in our AI-driven mission to improve workflows and patient care in the battle against cancer.
  • At AIxMed, she will apply these strong credentials towards positioning the Company's technology at the leading edge of the Pathology digital revolution.

StatLab Medical Products acquires CellPath Ltd.

Retrieved on: 
Wednesday, June 8, 2022
Research, General Health, Oncology, Medical Devices, Hospitals, Other Manufacturing, Science, Surgery, Chemicals, Plastics, Medical Supplies, Manufacturing, Health, Leadership, Immunohistochemistry, Histology, Pathology, CEO, Multimedia, Cytopathology, Acquisition, Family, Management

StatLab Medical Products (StatLab) , an Audax Private Equity and Linden Capital Partners portfolio company and a leading developer and manufacturer of medical diagnostic supplies and equipment, today announced that it has acquired CellPath Ltd. (CellPath) , a UK-based manufacturer and supplier of products and services focused on the histology and cytology markets.

Key Points: 
  • StatLab Medical Products (StatLab) , an Audax Private Equity and Linden Capital Partners portfolio company and a leading developer and manufacturer of medical diagnostic supplies and equipment, today announced that it has acquired CellPath Ltd. (CellPath) , a UK-based manufacturer and supplier of products and services focused on the histology and cytology markets.
  • With this acquisition, StatLab expands its reach into Europe, adds key injection molding manufacturing capabilities, and acquires proprietary products including the CellNass archiving service.
  • "We have long respected CellPath for their well-earned reputation of delivering innovative products that solve problems for labs, and are proud to welcome them to the StatLab family of brands, said Mike Karsonovich, CEO of StatLab.
  • Founded in 1976, StatLab Medical Products is leading the way in development and manufacturing of high-quality histology, cytology and immunohistochemistry diagnostic products.

ASP Health and Planet Innovation Receive 2022 Medical Design Excellence Award

Retrieved on: 
Tuesday, May 10, 2022
Bronze Award, ROSE, PLANET, Health, ASC, Engineering, FNA, Physician, Patient, Patient safety, Anesthesia, HEALTH, Partnership, FDA, Cancer, Diagnosis, Hospital, Pressure, ASP, PI, American Society of Cytopathology, Marketing, Medtech, Society, MDEA, CEO, Technology, Research, AI, Collection, Risk, Medicine, Medical device, Pharmaceutical industry, Medical imaging, Cytopathology

EVANSTON, Ill. and IRVINE, Calif., May 10, 2022 /PRNewswire-PRWeb/ -- ASP Health, a private medical device company focused on developing and commercializing innovative sample preparation technology to enhance and expand cancer diagnosis, and Planet Innovation (PI), ASP Health's product development and commercialization partner, have received the Bronze Award in the Testing and Diagnostic Product and Systems category for their innovative, FDA-registered automated sample preparation system. The company introduced its novel system at the American Society of Cytopathology (ASC) 69th Annual Scientific Meeting in November 2021.

Key Points: 
  • The ASP Health platform was honored in the 2022 Medical Design Excellence Awards (MDEA), the premier awards program for the MedTech industry.
  • ABOUT ASP HEALTH ASP Health is a private medical device company focused on developing and commercializing innovative sample preparation technology to enhance and expand cancer diagnosis.
  • ASP Health partners with Planet Innovation , a world-class company known for creating breakthrough products and commercially successful businesses.
  • ABOUT PLANET INNOVATION Planet Innovation (PI) is a healthtech innovation and commercialization company that exists to create breakthrough products and commercially successful businesses that transform industries and have a positive impact on the world.

Explore Developments in Timely Diagnosis Technologies on Advancements TV Series

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Clinical medicine, Medicine, Anatomical pathology, Cell biology, Cytopathology, Biopsy, Ted Danson, Pathology

JUPITER, Fla., July 26, 2021 /PRNewswire-PRWeb/ -- Scheduled to broadcast Q4/2021, the award-winning series, Advancements with Ted Danson, will focus on supporting technologies for timely diagnosis.

Key Points: 
  • JUPITER, Fla., July 26, 2021 /PRNewswire-PRWeb/ -- Scheduled to broadcast Q4/2021, the award-winning series, Advancements with Ted Danson, will focus on supporting technologies for timely diagnosis.
  • In this segment, viewers will learn about ROSE an established Rapid On-site Evaluation procedure for evaluation of biopsy specimens at the time of collection.
  • Hearing from experts in the field, audiences will see how ROSE helps experienced Cytopathologists determine if the content is adequate to provide a diagnosis.
  • For more information, visit: http://www.roseaid.com
    About Advancements and DMG Productions:
    The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies.

Explore Developments in Timely Diagnosis Technologies on Advancements TV Series

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Clinical medicine, Medicine, Anatomical pathology, Cell biology, Cytopathology, Biopsy, Ted Danson, Pathology

JUPITER, Fla., July 24, 2021 /PRNewswire-PRWeb/ -- Scheduled to broadcast Q4/2021, the award-winning series, Advancements with Ted Danson, will focus on supporting technologies for timely diagnosis.

Key Points: 
  • JUPITER, Fla., July 24, 2021 /PRNewswire-PRWeb/ -- Scheduled to broadcast Q4/2021, the award-winning series, Advancements with Ted Danson, will focus on supporting technologies for timely diagnosis.
  • In this segment, viewers will learn about ROSE an established Rapid On-site Evaluation procedure for evaluation of biopsy specimens at the time of collection.
  • Hearing from experts in the field, audiences will see how ROSE helps experienced Cytopathologists determine if the content is adequate to provide a diagnosis.
  • For more information, visit: http://www.roseaid.com
    About Advancements and DMG Productions:
    The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies.

Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Oncology, Cancer, Lung cancer, Infectious causes of cancer, Health, Neoplasms, Carcinoma, Cytopathology, Small-cell carcinoma, G1 Therapeutics

This "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape.

Key Points: 
  • This "Extensive-Stage Small Cell Lung Cancer (ESCLC) - Pipeline Insight, 2021" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape.
  • "Extensive-Stage Small Cell Lung Cancer (ESCLC)- Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape is provided which includes the disease overview and Extensive-Stage Small Cell Lung Cancer (ESCLC) treatment guidelines.
  • Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

Retrieved on: 
Thursday, June 10, 2021
Cancer, Lung cancer, Clinical medicine, Kidney cancer, Neoplasms, Carcinoma, Cytopathology, Small-cell carcinoma, Renal cell carcinoma

HC-5404-FU is an endoplasmic reticulum (ER) stress modulator, and the Investigational New Drug (IND) application received the greenlight from the U.S. Food and Drug Administration (FDA) in late 2020.

Key Points: 
  • HC-5404-FU is an endoplasmic reticulum (ER) stress modulator, and the Investigational New Drug (IND) application received the greenlight from the U.S. Food and Drug Administration (FDA) in late 2020.
  • The Phase 1a trial is designed as a dose escalation study across patients with specific tumor types, inclusive of renal cell carcinoma (RCC), gastric cancer (GC), breast cancer (MBC), and small-cell lung cancer (SCLC).
  • The initiation of this first-in-human study is a significant milestone for HiberCell as we move our platform of stress modulators into the clinic.
  • To that end, HiberCell is developing therapies that blunt the omnipresent stress-mediated adaptive response of cancer cells.

OptraSCAN Announces CytoSiA - A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Microscopy, Pathology, Biology, Infectious causes of cancer, Digital pathology, Clinical medicine, Cytopathology, Liquid-based cytology, Pap test

SAN JOSE, Calif. and PUNE, India, May 25, 2021 /PRNewswire/ -- OptraSCAN , the leading On-Demand Digital Pathology solution provider, today announced its intelligent solution CytoSiA for rapid yet affordable scanning and analyzing of liquid-based cytology slides and pap-smears.

Key Points: 
  • SAN JOSE, Calif. and PUNE, India, May 25, 2021 /PRNewswire/ -- OptraSCAN , the leading On-Demand Digital Pathology solution provider, today announced its intelligent solution CytoSiA for rapid yet affordable scanning and analyzing of liquid-based cytology slides and pap-smears.
  • Witharange of scanning devices handling as low as 50 slides a week to 5000 slides a week at an extremely affordable price," he further added.
  • OptraSCANS's digital scanners can scan cytology slides of size 15x15 mm area at 40x magnification in less than 60 seconds while generating the highest quality image.
  • "Our team has developed an intelligent imaging technology that transforms physical glass cytology slides into digital images with exceptional clarity.

OptraSCAN Announces CytoSiA - A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Microscopy, Pathology, Biology, Infectious causes of cancer, Digital pathology, Clinical medicine, Cytopathology, Liquid-based cytology, Pap test

SAN JOSE, Calif. and PUNE, India, May 25, 2021 /PRNewswire/ -- OptraSCAN , the leading On-Demand Digital Pathology solution provider, today announced its intelligent solution CytoSiA for rapid yet affordable scanning and analyzing of liquid-based cytology slides and pap-smears.

Key Points: 
  • SAN JOSE, Calif. and PUNE, India, May 25, 2021 /PRNewswire/ -- OptraSCAN , the leading On-Demand Digital Pathology solution provider, today announced its intelligent solution CytoSiA for rapid yet affordable scanning and analyzing of liquid-based cytology slides and pap-smears.
  • Witharange of scanning devices handling as low as 50 slides a week to 5000 slides a week at an extremely affordable price," he further added.
  • OptraSCANS's digital scanners can scan cytology slides of size 15x15 mm area at 40x magnification in less than 60 seconds while generating the highest quality image.
  • "Our team has developed an intelligent imaging technology that transforms physical glass cytology slides into digital images with exceptional clarity.

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021

Retrieved on: 
Wednesday, May 19, 2021
Lung cancer, Cancer, Carcinoma, Cytopathology, Small-cell carcinoma, Clinical medicine, Medicine

"With new data from across our oncology portfolio, we are proud to drive the advancement of the potential next generation of targeted cancer treatments for patients who need it most.

Key Points: 
  • "With new data from across our oncology portfolio, we are proud to drive the advancement of the potential next generation of targeted cancer treatments for patients who need it most.
  • "\nAdditional research to be presented at ASCO includes updated safety and efficacy data from the first-in-human (FIH) study of AMG 757 (tarlatamab) in small cell lung cancer (SCLC).
  • Administer corticosteroids for severe or life-threatening CRS.\nNeurological Toxicities: Approximately 65% of patients receiving BLINCYTOin clinical trials experienced neurological toxicities.
  • A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data.